Mercados españoles cerrados en 7 hrs 57 min

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
67,49-0,20 (-0,30%)
Al cierre: 4:00PM EDT
Inicia sesión para publicar un mensaje.
  • P
    P509$
    $SLS conversation
    $AGEN wow another Peptide Cancer Vaccine company picked up $200M upfront from $BMY --- $SLS drug Gps, a WT1 oncogene Peptide Vaccine in combination with Opdivo for Ovarian cancer and Mesothelioma, recently announced 25 month survival for a Sarcomatoid Meso patient.
  • j
    jim
    $SLS conversation
    Thought $sls would get bought before $adxs / $mrk and $bmy both want gps
  • A
    Andy
    Outstanding interview by Walters…all on our Telegram Group. Clearly a frustrated genius as $BMY wouldn’t let him pursue the ‘novel’ treatments he is now developing at Portage Biotech. Clearly very confident on PORT-2 and 3.
  • R
    Real Immunotrader 10
    $SLS conversation
    $mrk or $bmy would like to own this right now and would pay billions
  • g
    greg
    $SLS conversation
    Nom Nom Nom - Trial Result announcement in Mere days Gps in Combination with $Mrk and $BMY
    A Immunotherapy cure for Mesothelioma
    A Immunotherapy cure for end stage Ovarian Cancer Patients
  • D
    Dude
    $SLS conversation
    $sls has two combination trials due for readout in Q2 - Gps a powerful t cell cd3,4,8 generator combined with $bmy / Opdivo for Mesothelioma end stage patients and $Mrk Keytruda for Ovarian cancer patients who have no other treatment options. Results Imminent.
  • D
    Dude
    Only the most brain dead half wit would let one share go before the two Checkpoint $bmy $mrk results this month. And it doesn’t take much to recognize shares will be hard to find given this super low volume and all the desperate short covering that needs to happen.
  • R
    Real Immunotrader 10
    $SLS conversation
    There are so many possibilities for new news; enrollment data, trial data, licensing news, partnership news, more milestone money.
    Whatever happens on june 3 - we know 100% for sure the $bmy $mrk combo results are due in Q2.
    Both trials treat patients who have no other treatment options- each readout can launch this.
  • j
    jim
    $SLS conversation
    There are billions of reasons $SlS is in its strongest financial position ever. Every day closer to making the obvious known, this is a significant cancer cure. Ez to see this is worth billions. Projected annual revs of $600M just in AML - ot should be trading for 10x right now in this market when Time is money - Dd - we have - multiple confirmatory studies on Gps engaging and activating patients own immune system. Gps extended Os to 21 months for end stage secondary aml, usually older patients who have exhausted all other treatments. The efficacy, safety profile and relatively inexpensive cost will make this the new standard of care for 60,000 patients each year.
    Combination trial partnerships with $mrk $bmy $roche
  • R
    Real Immunotrader 10
    $SLS conversation
    There are so many possibilities for new news; enrollment data, trial data, licensing news, partnership news, more milestone money.
    Whatever happens on june 3 - we know 100% for sure the $bmy $mrk combo results are due in Q2.
    Both trials treat patients who have no other treatment options- each readout can launch this.
    A keytruda combo that works in phase 2 for Ovarian cancer patients who have no other treatment options is a billion dollar asset.
  • j
    jim
    $SLS conversation
    Ty to barry INCOMING CATASLYSTS
    🚀 2 updates on combo trials with $MRK's Keytruda and $BMY before July 2021, preliminary results showed 100% progression free survival in solid tumors, due date just confirmed
    🚀 Unusual Shareholder Update Call on Thursday, June 3, 2021 Premarket, only 5 days before the Annual Shareholder Meeting
    🚀 New licensing deals to be finalized
    🚀$glsi like trial data in Q4 $1B Value
    🚀$cpxx / $jazz in Q4/Q1 $1.5B comp

    FUNDAMENTALS
    🚀 New patent granted for GPS in combo with checkpoint inhibitor therapies
    🚀 Billion dollar pipeline for at least 5 indications (and probably 20+) with proven safety and stellar efficacy
    🚀 $202M licensing deal with 3D Med plus 10% royalties for every sale in The Greater China, $8M upfront payment received

    TECHNICALS
    🚀 Record high Short Squeeze Score
    🚀 $28M cash and micro burnrate
    🚀 100% Strong Buy
    🚀 Micro float of 15M
    🚀 Overshorted and undervalued with a ridiculous $180M marketcap

    ALSO
    🚀 Institutionals piling in and loading up
  • j
    jim
    $SLS conversation
    Amost 3 years of cash, a $200M licensee making payments - fda just 10-12 months away + two Imminently due combo trials with $Mrk and $BMY for patients with no therapy options. $SlS shares are worth more, much more than these shorts sold for them down to and the desperation shows. Two Live Corp updates in Early June, very unusual for sls.
    When the P3 comes in everyone, ever single person who knows about this company will be kicking themselves they did not buy and hold more of these in the single digits. A fact:
    Phase 3 assets nearing completion are worth more than this, much more.
  • s
    sWINger
    $SLS conversation
    Some decent DD for anyone interested https://www.reddit.com/r/WallStreetbetsELITE/comments/nbn9zn/low_float_cancer_cure_massive_catalysts_coming/ Thanks Barry Barry yesterday. Recap for potential investors here: Two updates on combo trials with $MRK and $BMY before July 2021 +++ 100% progression free survival in solid tumors +++ unusual Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET. 5 days before the Annual Shareholder Meeting +++ Record high Short Squeeze Score +++ $28M cash and low burnrate +++ Institutionals piling in and loading up big time +++ low float +++ with a $120M waaaay undervalued and overshorted +++ blockbuster pipeline with proven safety and stellar effecacy +++ $202M licensing deal with 3D Med plus 10% royalties for every sale in The Greater China +++ newly incoming licensing deals ...
    The choice is yours.

    r/WallStreetbetsELITE - Low Float - Cancer Cure - Massive Catalysts Coming June 3rd Shareholder Update Scheduled right before annual meeting on June 8th. Somethings up! Over a million short shares on a 15 million float. Easy to push over $100 really
    31 votes and 33 comments so far on Reddit
  • s
    sWINger
    $SLS conversation
    Tripling In now - low volume take down
    Here for the $MRK and $BMY Results by end of First Half these shares will be trading much much higher
  • B
    Barry
    $SLS conversation
    $XBI Early birds catch the worm. Here's why June will be pretty stellar for $SLS:

    INCOMING CATASLYSTS
    🚀 2 updates on combo trials with $MRK's Keytruda and $BMY before July 2021, preliminary results showed 100% progression free survival in solid tumors, due date just confirmed
    🚀 Unusual Shareholder Update Call on Thursday, June 3, 2021 Premarket, only 5 days before the Annual Shareholder Meeting
    🚀 New licensing deals to be finalised

    FUNDAMENTALS
    🚀 New patent granted for GPS in combo with checkpoint inhibitor therapies
    🚀 Billion dollar pipeline for at least 5 indications (and probably 20+) with proven safety and stellar efficacy
    🚀 $202M licensing deal with 3D Med plus 10% royalties for every sale in The Greater China, $8M upfront payment received

    TECHNICALS
    🚀 Record high Short Squeeze Score
    🚀 $28M cash and micro burnrate
    🚀 100% Strong Buy
    🚀 Micro float of 15M
    🚀 Overshorted and undervalued with a ridiculous $180M marketcap

    ALSO
    🚀 Institutionals piling in and loading up
  • j
    jim
    $SLS conversation
    Solid Tumors - Refractory - Ovarian and Mesothelioma Cancer Patients who have exhausted all treatment Options --> two trial Results due, $BMY Nivo $MRK pembro + GPS - Early Results Here
    SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications. 12/21/20 - Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Progression Free Survival at 6 Weeks -

    - Early Data from Mesothelioma Study of GPS in Combination with Opdivo® Shows Clinically Intriguing Activity with Median Progression Free Survival of at Least 10 Weeks -

    - Updated Data Expected in First Half of 2021 -

    NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced initial data from two clinical studies of galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies in patients with two different types of advanced solid cancers who had exhausted their standard therapy options.

    In the first study, a phase 1/2 ‘basket’ trial of GPS in combination with the checkpoint inhibitor pembrolizumab (Keytruda), which is conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), the first set of evaluable patients (n = 8) diagnosed with 2nd or 3rd line WT1(+) relapsed or refractory metastatic ovarian cancer demonstrated a disease control rate (the sum of overall response rate and rate of stable disease) of 87.5% with a median follow-up of 9.4 weeks. In this difficult to treat patient population, at the first assessment time-point of 6 weeks post-therapy initiation, 100% of the patients were free of disease progression. Using a validated immunohistochemistry (IHC) assay during the screening period, the rate of WT1 positivity in this ovarian cancer patient population was approximately 70%. Six of the eight evaluable patients are continuing to receive GPS plus pembrolizumab. Enrollment is continuing with a target of a total of 20 patients. More mature clinical and immunobiological data are expected to be announced by the end of the second quarter of 2021.

    In the second study, a Phase 1 investigator-sponsored clinical trial (IST) of GPS in combination with the checkpoint inhibitor nivolumab (Opdivo) in patients with macroscopic measurable deposits of malignant pleural mesothelioma (MPM) who were either refractory to or relapsed after frontline tri-modality standard therapy, the first set of evaluable patients (n = 3) had a median progression free survival of at least 10 weeks since therapy initiation. In primary refractory MPM patients, any prolongation of progression-free interval greater than 8 weeks would be considered clinically meaningful, considering the current lack of effective therapies. All patients had the epithelioid variant of MPM, a tumor which is universally expressing WT1. Moreover, in this study, GPS was found to be appropriately immunogenic, leading to the emergence of antigen (WT1)-specific CD4+ T-memory cell responses at 3 months post-therapy initiation. Additional MPM patients are currently being enrolled; completion of study enrollment (target total n = 10) and more mature clinical and immunobiological data are expected by the end of the second quarter of 2021.

    In both studies, the safety profile of the combination of GPS with the checkpoint inhibitor was similar to that seen with checkpoint inhibitors alone, with the addition of only low grade, transitory local reactions at the site of injection of GPS, consistent with previously performed clinical studies of GPS.

    “These early data confirm the tolerability profile seen in earlier studies of GPS, which is one of the primary endpoints in these solid cancer trials, in a variety of cancer indications, even in the most refractory patients who underwent numerous prior therapies,” commented Jeffrey S. Weber, MD, PhD, Deputy Director of the Perlmutter Cancer Center at New York University (NYU)-Langone Health, co-Director of its Melanoma Research Program Center and Chair of SELLAS’ Scientific Advisory Board. “These safety findings are accompanied by promising early indications of an efficacy signal for patients with advanced metastatic disease, whose management is extremely challenging even with checkpoint inhibitor monotherapy.”

    “We are encouraged by the data shown in these two studies of GPS in combination with checkpoint inhibitors and look forward to additional data from thes
  • B
    Barry
    $SLS conversation
    Recap for potential investors here, and longs getting impatient :

    Two updates on combo trials with $MRK and $BMY before July 2021 +++ 100% progression free survival in solid tumors +++ unusual Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET. 5 days before the Annual Shareholder Meeting +++ Record high Short Squeeze Score +++ $28M cash and low burnrate +++ Institutionals piling in and loading up big time +++ low float +++ with a $120M waaaay undervalued and overshorted +++ blockbuster pipeline with proven safety and stellar effecacy +++ $202M licensing deal with 3D Med plus 10% royalties for every sale in The Greater China +++ newly incoming licensing deals ...
    The choice is yours.
  • D
    Dude
    $SLS conversation
    2 Trading Days Remain / long weekend $sls has two combination trials due for readout in Q2 - Gps a powerful t cell CD 3,4,8 generator combined with $bmy / Opdivo for Mesothelioma end stage patients and $Mrk Keytruda for Ovarian cancer patients who have no other treatment options. Results Imminent. hedge funds already moving into early positions.
  • D
    Dude
    $SLS conversation
    REPEAT Investment Advice: CEO Confirmed Later this quarter Ie in only 3 weeks'ish SLS shares will be going Vertical, Destination SPACE Travel with the Keytruda $MRK and Opdivo $BMY trial results. This is as cheap as they'll get. Over shorted Oversold And about to bounce. $BCTX Launched 200% YESTERDAY on similar combo data.
  • s
    sWINger
    $SLS conversation
    $sls has two combination trials due for readout in Q2 - Gps a powerful t cell cd3,4,8 generator combined with $bmy / Opdivo for Mesothelioma end stage patients and $Mrk Keytruda for Ovarian cancer patients who have no other treatment options. Results Imminent.